Data News > Investigation Commenced on Johnson & Johnson Stock, Investors Alerted
- Levi & Korsinsky, Pomerantz LLP, and Bronstein, Gewirtz & Grossman, LLC are all investigating Johnson & Johnson for potential securities law violations
- Johnson & Johnson paused U.S. External Evaluation and VARIPULSE™ cases due to reported neurovascular events
- JNJ stock underperformed in 2024, losing 7% while S&P 500 gained 23%
- FDA accepted J&J's filing for autoimmune disease drug Nipocalimab
- Dow Jones Industrial Average reached record highs, impacting J&J stock performance
Levi & Korsinsky, Pomerantz LLP, and Bronstein, Gewirtz & Grossman, LLC have all initiated investigations into Johnson & Johnson (JNJ) for potential violations of federal securities laws. This comes after J&J announced a temporary pause on the U.S. External Evaluation and VARIPULSE™ cases in response to four reported neurovascular events. Investors who have lost money on their Johnson & Johnson investment are encouraged to contact these firms for further information and assistance.
In 2024, Johnson & Johnson stock (JNJ) experienced a loss of around 7%, significantly underperforming the broader S&P 500 index, which saw a gain of 23% during the same period. This poor performance contrasts with other pharmaceutical giants like Eli Lilly and AbbVie, who saw stock increases of 31% and 15% respectively. Investors are now left wondering what the future holds for JNJ stock in 2025.
Additionally, J&J recently made a filing seeking FDA approval for nipocalimab, an autoimmune disease drug intended to treat generalized myasthenia gravis in a wide range of antibody-positive patients. This development could have significant implications for the company's future performance and stock value.
As the Dow Jones Industrial Average continues to reach record highs, surpassing 45,000 in December 2024, the broader market conditions have a direct impact on the performance of individual stocks like Johnson & Johnson. Investors are advised to monitor market trends and developments closely to make informed decisions regarding their investment portfolios.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Investigation Commenced on Johnson & Johnson Stock, Investors Alerted
By KlickAnalytics Data Insights | January 10, 2025 08:05PM ET
Key Points
- Levi & Korsinsky, Pomerantz LLP, and Bronstein, Gewirtz & Grossman, LLC are all investigating Johnson & Johnson for potential securities law violations
- Johnson & Johnson paused U.S. External Evaluation and VARIPULSE™ cases due to reported neurovascular events
- JNJ stock underperformed in 2024, losing 7% while S&P 500 gained 23%
- FDA accepted J&J's filing for autoimmune disease drug Nipocalimab
- Dow Jones Industrial Average reached record highs, impacting J&J stock performance
Levi & Korsinsky, Pomerantz LLP, and Bronstein, Gewirtz & Grossman, LLC have all initiated investigations into Johnson & Johnson (JNJ) for potential violations of federal securities laws. This comes after J&J announced a temporary pause on the U.S. External Evaluation and VARIPULSE™ cases in response to four reported neurovascular events. Investors who have lost money on their Johnson & Johnson investment are encouraged to contact these firms for further information and assistance.
In 2024, Johnson & Johnson stock (JNJ) experienced a loss of around 7%, significantly underperforming the broader S&P 500 index, which saw a gain of 23% during the same period. This poor performance contrasts with other pharmaceutical giants like Eli Lilly and AbbVie, who saw stock increases of 31% and 15% respectively. Investors are now left wondering what the future holds for JNJ stock in 2025.
Additionally, J&J recently made a filing seeking FDA approval for nipocalimab, an autoimmune disease drug intended to treat generalized myasthenia gravis in a wide range of antibody-positive patients. This development could have significant implications for the company's future performance and stock value.
As the Dow Jones Industrial Average continues to reach record highs, surpassing 45,000 in December 2024, the broader market conditions have a direct impact on the performance of individual stocks like Johnson & Johnson. Investors are advised to monitor market trends and developments closely to make informed decisions regarding their investment portfolios.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.